With currently available biologics, patients with moderate to severe plaque psoriasis can achieve rapid and durable symptom relief and a sustained improvement in quality of life [1,2]. Using a case report, Ahmad Jalili, MD, illustrates how such ambitious treatment goals became reality for a patient with severe psoriasis vulgaris.
This case presentation was selected by PD Ahmad Jalili, MD, on behalf of AbbVie Switzerland and is for illustrative purposes only. For robust risankizumab efficacy and safety data, please refer to the clinical trials and the current SmPC [3].
Video duration: 11:19 minutes
Language: German
Literature:
1. Gordon KB, et al: Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebocontrolled and ustekinumab-controlled phase 3 trials. Lancet, 2018. 392(10148): 650-661.
2 Papp KA et al. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. Br J Dermatol, 2021.
3. Current SKYRIZI® (risankizumab) technical information available at www.swissmedicinfo.ch.
This article was written with the financial support of AbbVie AG, Cham.
Brief technical information Skyrizi®
CH-SKZD-210043_12/2021
The references can be requested by professionals at medinfo.ch@abbvie.com.
